

Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.  
A31386-A - 070165.0593

Serial No.  
09/855,886

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**  
(Use several sheets if necessary)

Applicants  
Colleri et al.

Filing Date  
May 15, 2001

Group  
1642

**U.S. PATENT DOCUMENTS**

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate

**FOREIGN PATENT DOCUMENT**

Document No.	Class	SubClass	Translator Yes No

**OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)**

	Taverna et al. (1997) "Is $\alpha 5$ integrin a tumor suppressor gene?", <i>Proceedings of the American Association for Cancer Research</i> 38: 290-291.
	Hynes et al. (1997) "Targeted mutations in integrins and their ligands: their implications for vascular biology", <i>Thrombosis and Haemostasis</i> 78: 83-87.
	Taverna et al. (2004) "Increased primary tumor growth in mice null for $\beta 3$ - $\beta 3$ / $\beta 5$ -integrins or selectins", <i>PNAS</i> 101: 763-768.
	Trikha et al. (2002) "Multiple roles for platelet GPIIb/IIIa and $\alpha v \beta 3$ integrins in tumor growth, angiogenesis, and metastasis", <i>Cancer Research</i> 62: 2824-2833.
	Lincoff et al. (2001) "Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization", <i>Circulation</i> 104: 163-167.
	Dean J. Kereiakes (2003) "Inflammation as a therapeutic target; a unique role for abciximab", <i>Supplement to AHJ</i> 146: 1-4.

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.